462
Views
9
CrossRef citations to date
0
Altmetric
Review

Genetic testing in women with breast cancer: implications for treatment

&
Pages 991-1002 | Received 04 Apr 2017, Accepted 29 Aug 2017, Published online: 08 Sep 2017

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Dan Xue, Pu Cheng, Mengjiao Han, Xiyong Liu, Lijun Xue, Chenyi Ye, Ke Wang & Jian Huang. (2018) An integrated bioinformatical analysis to evaluate the role of KIF4A as a prognostic biomarker for breast cancer. OncoTargets and Therapy 11, pages 4755-4768.
Read now

Articles from other publishers (8)

Vamika Karn, Sandhya Sandhya, Wayne Hsu, Deepak Parashar, Himanshu Narayan Singh, Niraj Kumar Jha, Saurabh Gupta, Navneet Kumar Dubey & Sanjay Kumar. (2022) CRISPR/Cas9 system in breast cancer therapy: advancement, limitations and future scope. Cancer Cell International 22:1.
Crossref
Daniela Ochoa, Christopher Jean-Louis, Krista Stephenson, Margaret Woods, Jill Kelsey & Ronda Henry-Tillman. (2022) What happens after referral? Completion rates of genetic counseling evaluations in breast cancer patients. Journal of the National Medical Association 114:1, pages 90-93.
Crossref
. (2021) BRCA1 and BRCA2 genes mutations among women with clinical signs of hereditary breast cancer in western Belarus. The Journal of V. N. Karazin Kharkiv National University, Series "Medicine":42.
Crossref
Priyanka Bobbili, Temitope Olufade, Maral DerSarkissian, Rahul Shenolikar, Hong Yu, Mei Sheng Duh & Nadine Tung. (2020) Adherence to National Comprehensive Cancer Network Guidelines for BRCA testing among high risk breast Cancer patients: a retrospective chart review study. Hereditary Cancer in Clinical Practice 18:1.
Crossref
Fernando Gonzalez-Salinas, Rocio Rojo, Claudia Martinez-Amador, Jessica Herrera-Gamboa & Victor Trevino. (2020) Transcriptomic and cellular analyses of CRISPR/Cas9-mediated edition of FASN show inhibition of aggressive characteristics in breast cancer cells. Biochemical and Biophysical Research Communications 529:2, pages 321-327.
Crossref
Mark Robson & Susan Domchek. (2019) Broad Application of Multigene Panel Testing for Breast Cancer Susceptibility—Pandora’s Box Is Opening Wider. JAMA Oncology 5:12, pages 1687.
Crossref
F. Cardoso, E. Senkus, A. Costa, E. Papadopoulos, M. Aapro, F. André, N. Harbeck, B. Aguilar Lopez, C.H. Barrios, J. Bergh, L. Biganzoli, C.B. Boers-Doets, M.J. Cardoso, L.A. Carey, J. Cortés, G. Curigliano, V. Diéras, N.S. El Saghir, A. Eniu, L. Fallowfield, P.A. Francis, K. Gelmon, S.R.D. Johnston, B. Kaufman, S. Koppikar, I.E. Krop, M. Mayer, G. Nakigudde, B.V. Offersen, S. Ohno, O. Pagani, S. Paluch-Shimon, F. Penault-Llorca, A. Prat, H.S. Rugo, G.W. Sledge, D. Spence, C. Thomssen, D.A. Vorobiof, B. Xu, L. Norton & E.P. Winer. (2018) 4th ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Annals of Oncology 29:8, pages 1634-1657.
Crossref
Stuart K. Kim. (2018) Identification of 613 new loci associated with heel bone mineral density and a polygenic risk score for bone mineral density, osteoporosis and fracture. PLOS ONE 13:7, pages e0200785.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.